Business
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden of Prader-Willi syndrome (PWS) and findings from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia associated PWS at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting 2025, which is being held May 13-16, in Montreal, Canada. Details of the presentations are as follows: ISPOR 2025 Title: Expected vs. Observed Mortality Rates, Expressed As Number Needed to Treat, From a Phase 3 Clinical Trial Program of Patients With Hyperphagia and Prader-Willi Syndrome Treated With Diazoxide Choline Extended Release (DCCR)Format: PosterSession: Poster Session 2Date/Time: May 14, 6:00 - 7:00 PM ETPresenter: Raj Gandhi, PharmD MBA Title: The Burden of Prader-Willi Syndrome on Patients and the Healthcare System: A Cross-Sectional Examination of Emergency Department Visits and Inpatient Stays in US claimsFormat: PosterSession: Poster Session 4Date/Time: May 15, 6:00 - 7:00 PM ETPresenter: Raj Gandhi, PharmD MBA About PWSThe Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition characterized by feelings of intense, persistent hunger, food pre-occupation, and an extreme drive to seek and consume food, which can severely diminish the quality of life for individuals with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. About VYKAT XRVYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated ...